Episode Description
Discover the revolutionary advancements in blood cancer treatment with Dr. Mark Fesler, a leading hematologist and oncologist at St. Luke's. We promise you'll gain a comprehensive understanding of the intricate phases of clinical trials, from safety assessments to efficacy evaluations. Dr. Fesler sheds light on the transformative shift from traditional cytotoxic drugs to cutting-edge immunotherapies, including checkpoint inhibitors, chimeric antigen T cells, and the promising bispecific antibodies that are changing the landscape of cancer care.